Daiichi Sankyo Europe, Gmbh, A Daiichi Sankyo Company

This study follows about 1,155 adults with HER2-low breast cancer that cannot be removed by surgery or has spread to other parts of the body. It compares how long people stay on a newer targeted drug (trastuzumab deruxtecan) versus standard chemotherapy before needing a different…

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer whose disease progressed after prior treatment with trastuzumab. Researchers will track how long patients stay on the targeted drug T-DXd before needing a different treatme…

This study looks at how well a three-medicine combination works for people with very high cholesterol who are at high risk for heart problems. About 2000 adults will take bempedoic acid plus ezetimibe and a statin. Researchers will check cholesterol levels after 8 weeks and 1 yea…